How Skin Cancer Is Treated

Treatments for skin cancer depend on the type of cancer, the stage, the size and location of the tumor, and its features. For basal cell carcinomas and squamous cell carcinomas, surgery (excision) or electrodesiccation and cautery of the cancer is often all that is needed. Mohs surgery is an additional option to reduce scarring. The treatment of melanoma also includes surgery, but typically with a wider excision. Depending on the cancer stage, additional treatments such as immunotherapy, targeted therapy, chemotherapy, and radiation therapy may be needed.

A team of doctors will work with you to determine your best skin cancer treatment plan. The team may include specialists such as a surgical oncologist, medical oncologist, radiation oncologist, dermatologist, plastic surgeon, and pathologist.

3 Common Types of Skin Cancer

Verywell / Emily Roberts


Both nonmelanoma (basal cell carcinoma and squamous cell carcinoma) and melanoma skin cancers can be successfully treated in almost all cases if they are diagnosed and treated when the tumor is relatively thin.

Surgery to remove the tumor is the standard treatment, but numerous other options are available as well.

The type of treatment method for nonmelanoma or melanoma cancers depends on how large the lesion is, where it is found on the body, and the specific type.

Simple Excision

Simple excision is done by injecting a local anesthetic and then surgically removing (excising) the tumor and a small area of normal-appearing tissue surrounding it. This is frequently done for smaller basal cell and squamous cell skin cancers.

Curettage and Electrodesiccation

Curettage and electrodesiccation is an option that may be used for treating very small basal cell and squamous cell carcinomas. During this procedure, the skin is numbed locally and a scalpel is used to shave off the lesion (curettage). Cautery (electrodesiccation) burns the surrounding tissue to stop bleeding and create a scab for when the area heals.

Mohs Surgery

Mohs surgery (microscopically controlled surgery) is a highly specialized surgical technique that may be used to excise melanoma-in-situ when the cancer involves an area where sparing tissue is important (e.g. the face).

The surgeon begins by excising visible cancer and sending the sample to the pathologist. The pathologist looks under the microscope to see if any tumor cells are near the margins (edges) of the sample removed. If so, further surgery is done, followed by pathological evaluation until all margins are clear. In some cases, many small excisions of tissue are done before clear margins are found.

The end result of this technique is less scarring than would occur if a surgeon simply took a wider margin of tissue to make sure that no cancer remained.

Surgery for Melanoma

Surgery for melanoma is extensive, and many people are surprised at the amount of tissue that is usually removed. A wide excision is recommended whenever possible.

Depending on the location and size of the melanoma, surgery may be done in the office or in an operating room. For small tumors, a local anesthetic may be injected, but other anesthesia techniques, such as a local nerve block or general anesthesia may be needed.

With larger melanomas, or melanomas in challenging areas, a plastic surgeon usually performs the procedure rather than a dermatologist, or the two will work together.

For this surgery, a wide elliptical incision is made, with consideration of the skin lines.

  • For melanoma in situ, a margin of 0.5 cm (about 1/4 of an inch) beyond the cancer is usually recommended.
  • A margin of 1 cm to 2 cm is usually recommended for tumors that are 1.01 mm to 2.0 mm thick, and a margin of 2 cm for those thicker than 2 mm.
  • Some surgeons are now using Mohs surgery for melanomas as well.
  • If a sentinel node biopsy is needed, this is often done at the time of surgery.

For smaller melanomas, the incision may be closed after surgery, similar to an incision done for another type of surgery. If a large amount of tissue is removed, closing with skin grafts or skin flaps may be required.

You may be very concerned when your surgeon discusses the amount of tissue that must be removed, but reconstruction for skin cancer has improved dramatically in recent years.

That said, reconstruction may need to be done in stages as healing occurs.

Side Effects

Side effects of any type of surgery for skin cancer may include bleeding or infection, scarring, as well as disfigurement.

Reconstructive procedures can do wonders in restoring appearance in even very extensive surgeries.

Specialist-Driven Procedures

There are a few procedures that are sometimes done as alternatives to surgically removing a tumor.

Some of these include:

  • Cryosurgery (freezing) is sometimes used to treat very small skin cancers, especially when a large number of precancerous and small cancerous lesions are present. As with surgery, cryosurgery can leave a scar. Cryosurgery may need to be repeated to eliminate any persistent lesions or to treat new precancerous ones.
  • Laser therapy (using a narrow beam of light) will vaporize the skin layers as deep as needed but not in totality. It works like cryosurgery but heals with minimum scarring. It can also be used as a cutting instrument to excise tissue instead of a scalpel.
  • Dermabrasion (using rough particles to rub away a tumor) is being evaluated as a possible way to prevent the development of skin cancers, but research as to whether this procedure makes a significant difference is still in its early stages. It has reportedly been used for very small skin cancers.
  • Topical chemotherapy with Efudex (topical 5-fluorouracil) is sometimes used to treat small, superficial basal cell carcinomas and small, superficial squamous cell carcinomas. Imiquimod may also be used to treat superficial basal cell carcinoma and superficial squamous cell carcinoma. The treatment of superficial SCC with either Efudex or imiquimod is an off-label use, though these treatments have proven effective in numerous medical studies.
  • The topical cream Aldara (imiquimod) is a type of immunotherapy drug that stimulates a person's own immune system to fight off cancer. It is currently only approved for treating superficial spreading basal cell carcinoma. In general, surgery is preferred, though imiquimod may be recommended in certain cases. Due to its mechanism of action, it does not scar. The cream is usually applied daily for five to six weeks.

Adjuvant Therapy

There are a number of treatment options for skin cancers that spread to distant regions of the body. These therapies are also sometimes used if there is no evidence that cancer has spread.

With early-stage melanomas (stage 0 and stage I), surgery may be the only treatment needed.

Intermediate stage melanomas (such as stage II and stage III) frequently recur after surgery. The risk of recurrence is greater the higher the stage of the tumor and if the tumor has spread to any lymph nodes. After surgery, additional treatment with immunotherapy, targeted therapy, and/or chemotherapy may be used to target any areas of cancer that remain in the body but are too small to be detected with imaging tests.

When treatments are used in this way, they are considered adjuvant therapies.

For stage IV melanomas, surgery alone is insufficient to treat cancer, and a combination of these therapies is needed. 


Immunotherapy (also called targeted or biologic therapy) helps the body's immune system find and attack cancer cells. It uses materials made by the body and modified in a laboratory to boost, target, or restore immune function. 

There are several treatments that classify as immunotherapies. With melanoma, there are two major categories (as well as others being evaluated in clinical trials):

  • Immune checkpoint inhibitors: Our bodies have the potential to fight cancer, but cancer cells find a way to hide from the immune system. These drugs work by, essentially, taking the brakes off the immune system so that it can fight off cancer cells. Keytruda (pembrolizumab) is a checkpoint inhibitor used to treat melanoma and squamous cell skin cancers. The checkpoint inhibitor Opdualag (nivolumab and relatlimab) may also be used.
  • Cytokines (such as interferon alfa-2b and interleukin-2) work non-specifically to bolster the immune system to fight off any invader, including cancer cells.

Immunotherapy is the standard of care and can be used alone either as adjuvant treatment in localized or in metastatic melanomas. Immunotherapy may also be used in combination with surgery and/or chemotherapy, or as part of a clinical trial. Many other treatments are being tested, including therapeutic vaccines and oncolytic viruses.

Side effects of these treatments vary. They can include fatigue, fever, chills, headache, memory difficulties, muscle aches, and skin irritation. Occasionally, side effects from immunotherapy can include a change in blood pressure or increased fluid in the lungs. Adverse reactions can sometimes become severe or life-threatening and can lead to death.


Chemotherapy is the use of drugs to kill any rapidly dividing cells in the body. This can be quite helpful for destroying cancer cells, but healthy cells divide as well—and the healthy cells that divide rapidly are often disrupted by chemotherapy. This gives rise to common chemotherapy side effects, such as low blood counts, hair loss, and nausea.

Chemotherapy may be given when there is a high risk of cancer recurring (as adjuvant therapy) or when cancer has metastasized. When given for metastatic disease, chemotherapy cannot cure cancer but can often prolong life and reduce symptoms.

Chemotherapy may be given in a number of different ways:

  • Topically: Topical 5-fluorouracil for is used for treating extensive basal cell carcinoma.
  • Intravenously: Chemotherapy delivered through the bloodstream targets cancer cells wherever they happen to be and is a mainstay for cancers that have metastasized to a number of different areas.
  • Intrathecally: For skin cancer metastases to the brain or spinal cord, chemotherapy may be injected directly into the cerebrospinal fluid. (Due to the presence of a network of tight capillaries known as the blood-brain barrier, many types of chemotherapy do not effectively penetrate into the brain.)
  • Intraperitoneal: For melanomas that have spread within the abdomen, chemotherapy may be given directly into the peritoneal cavity.
  • Into a limb: For cancers present in an arm or leg, a tourniquet may be applied and a higher dose of chemotherapy injected into the arm or leg than would otherwise be possible if given through a vein (isolated limb perfusion, ILP, and isolated limb infusion, ILI).​

Targeted Therapy

Targeted therapies are drugs that zero in on specific molecular pathways involved in the growth of cancer cells. In this way, they do not "cure" cancer, but may halt its progression for some people. Since these treatments have specific cancer (or cancer-related) targets, they often—but not always—have fewer side effects than traditional chemotherapy.

There are two primary categories of drugs now used (with others in clinical trials) including:

  • Signal transduction inhibitor therapy: These drugs target cellular communication pathways between cancer cells that are needed for the growth of some melanomas. Zelboraf (vemurafenib) and Taflinar (dabrafenib) may be effective for people who have tumors that test positive for changes in BRAF. The targeted drugs Mekinist (trametinib) and Cotellic (cobimetinib) may also be used.
  • Angiogenesis inhibitors: In order for tumors to grow and spread, new blood vessels must be formed (a process referred to as angiogenesis). Angiogenesis inhibitors work by preventing the formation of new blood vessels, essentially starving a tumor so it cannot grow. Side effects can sometimes be serious and include problems such as high blood pressure, bleeding, and rarely, bowel perforation.

Radiation Therapy

Radiation therapy is the use of high-energy X-rays or other particles to kill cancer cells. The most common type of radiation treatment is external-beam radiation therapy, which is radiation given from a machine outside the body.

Radiation may also be given internally via seeds that are implanted in the body (brachytherapy).

With melanoma, radiation may be given when cancer has spread to lymph nodes, after a lymph node dissection (with or without chemotherapy or immunotherapy). It is used most commonly as palliative therapy to reduce pain or prevent fractures due to bone metastases, rather than to treat skin cancer directly.

Clinical Trials

There are many clinical trials in progress that are looking for newer and better treatments for skin cancer, and the National Cancer Institute currently recommends that everyone diagnosed with melanoma consider the possibility of joining one. 

The treatment of cancer is changing very rapidly. The immunotherapy and targeted therapies currently used for treating melanoma were unheard of a decade ago, and even a few short years ago were only available in clinical trials.

Some people have had what oncologists call a "durable response" to treatment with these drugs, essentially—and cautiously—suggesting their effectiveness as a cure. This is true even for people with very advanced stage metastatic melanomas. Though these individuals remain the exceptions and not the norm, this is promising.

Oftentimes, the only way a person can receive a newer treatment is by being enrolled in a clinical trial. There are many myths about clinical trials, and many people are nervous about taking part in one. It may be helpful to understand that, unlike clinical trials of the past, many of these treatments are designed very precisely to target abnormalities in melanoma cells. Because of this, they are much more likely to be of benefit to a person receiving them as part of a research study than in the past.

Complementary Medicine (CAM)

We do not currently have any alternative cancer treatments that work to treat skin cancer, but some of these integrative therapies for cancer may be helpful in reducing the symptoms of cancer and cancer treatments. Options such as meditation, yoga, prayer, massage therapy, acupuncture, and more are now offered at many of the larger cancer centers.

It's important to note that some dietary supplements, as well as vitamin and mineral preparations, could interfere with cancer treatment. Some of the supplements may also increase the risk of bleeding after surgery. It's important to talk to your oncologist before taking any over-the-counter or nutritional supplements.

Frequently Asked Questions

  • What are the benefits of Mohs surgery?

    The main advantage is that Mohs surgery allows doctors to more precisely remove just the cancerous tissue while leaving healthy tissue in place. New procedures also ensure very quick testing, so you spend a short time in surgery.

44 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Gruber P, Shah M, Zito PM. Cancer, Skin (Integument). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from:

  2. Prickett KA, Ramsey ML. Mohs Micrographic Surgery. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from:

  3. Samarasinghe V, Madan V. Nonmelanoma skin cancerJ Cutan Aesthet Surg. 2012;5(1):3–10. doi:10.4103/0974-2077.94323

  4. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician.

  5. Reschly MJ, Shenefelt PD. Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas. J Drugs Dermatol.

  6. Ho C, Argáez C. Mohs Surgery for the Treatment of Skin Cancer: A Review of Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Available from:

  7. Joyce KM. Surgical Management of Melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 7.Available from: 10.15586/codon.cutaneousmelanoma.2017.ch7

  8. Rutkowski P, Zdzienicki M, Nowecki ZI, Van Akkooi AC. Surgery of primary melanomasCancers (Basel). 2010;2(2):824–841. Published 2010 May 11. doi:10.3390/cancers2020824

  9. Tchernev G, Voicu C, Mihai M, et al. Basal Cell Carcinoma Surgery: Simple Undermining Approach in Two Patients with Different Tumour LocationsOpen Access Maced J Med Sci. 2017;5(4):506–510. Published 2017 Jul 24. doi:10.3889/oamjms.2017.143

  10. Nahhas AF, Scarbrough CA, Trotter S. A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin CancersJ Clin Aesthet Dermatol.

  11. Bagaria SP, Faries MB, Morton DL. Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer InstituteJ Surg Oncol. 2010;101(8):669–676. doi:10.1002/jso.21581

  12. Dabek RJ, Baletic N, McUmber H, et al. Development of a primary melanoma in situ within a full-thickness skin graft overlying a free muscle flap: a case reportCase Reports Plast Surg Hand Surg. 2018;5(1):23–26. Published 2018 Apr 6. doi:10.1080/23320885.2018.1452615

  13. Clune JE, Narayan D. Surgical reconstruction in melanoma. Curr Probl Cancer.

  14. Lee EH, Klassen AF, Lawson JL, Cano SJ, Scott AM, Pusic AL. Patient experiences and outcomes following facial skin cancer surgery: A qualitative study [published correction appears in Australas J Dermatol. 2017 May;58(2):160]. Australas J Dermatol. 2016;57(3):e100–e104. doi:10.1111/ajd.12323

  15. Prohaska J, Badri T. Cryotherapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from:

  16. Soleymani T, Abrouk M, Kelly KM. An Analysis of Laser Therapy for the Treatment of Nonmelanoma Skin CancerDermatol Surg. 2017;43(5):615–624. doi:10.1097/DSS.0000000000001048

  17. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142(8):976-982. doi:10.1001/archderm.142.8.976

  18. Naik MP, Mehta A, Abrol S, Kumar S, Gupta VS. Topical 5% 5-fluorouracil in the treatment of multifocal basal cell carcinoma of the face: A novel chemotherapeutic approach. Orbit.

  19. Florin, V., Desmedt, E., Vercambre-Darras, S. et al. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 30, 1641–1645 (2012).

  20. Sapijaszko MJ. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett.

  21. Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literatureClin Epidemiol. 2016;8:109–122. Published 2016 May 26. doi:10.2147/CLEP.S99021

  22. Rueth NM, Cromwell KD, Cormier JN. Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am. 2015;24(2):359–377. doi:10.1016/j.soc.2014.12.012

  23. Paulson KG, Lahman MC, Chapuis AG, Brownell I. Immunotherapy for skin cancer. Int Immunol.

  24. Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol.

  25. Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne).

  26. Nicholas C, Lesinski GB. Immunomodulatory cytokines as therapeutic agents for melanomaImmunotherapy. 2011;3(5):673–690. doi:10.2217/imt.11.45

  27. Woller N, Gürlevik E, Ureche CI, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccinesFront Oncol. 2014;4:188. Published 2014 Jul 21. doi:10.3389/fonc.2014.00188

  28. Barber FD. Adverse Events of Oncologic Immunotherapy and Their ManagementAsia Pac J Oncol Nurs. 2019;6(3):212–226. doi:10.4103/apjon.apjon_6_19

  29. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol.

  30. Prince GT, Cameron MC, Fathi R, Alkousakis T. Topical 5-fluorouracil in dermatologic disease. Int J Dermatol.

  31. Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapyInt J Cancer. 2016;139(6):1195–1201. doi:10.1002/ijc.30147

  32. Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapyJ Gastrointest Oncol. 2016;7(1):45–57. doi:10.3978/j.issn.2078-6891.2015.111

  33. Cecchini S, Sarti D, Ricci S, et al. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanomaWorld J Clin Oncol. 2015;6(4):57–63. doi:10.5306/wjco.v6.i4.57

  34. Artemov A, Aliper A, Korzinkin M, et al. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activationOncotarget. 2015;6(30):29347–29356. doi:10.18632/oncotarget.5119

  35. Li C, Chi S, Xie J. Hedgehog signaling in skin cancersCell Signal. 2011;23(8):1235–1243. doi:10.1016/j.cellsig.2011.03.002

  36. Johnson KE, Wilgus TA. Multiple roles for VEGF in non-melanoma skin cancer: angiogenesis and beyondJ Skin Cancer. 2012;2012:483439. doi:10.1155/2012/483439

  37. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directionsInt J Med Sci. 2012;9(3):193–199. doi:10.7150/ijms.3635

  38. Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?.

  39. Wróbel S, Przybyło M, Stępień E. The Clinical Trial Landscape for Melanoma TherapiesJ Clin Med. 2019;8(3):368. Published 2019 Mar 15. doi:10.3390/jcm8030368

  40. Yu C, Liu X, Yang J, et al. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic MelanomaFront Immunol. 2019;10:990. Published 2019 May 7. doi:10.3389/fimmu.2019.00990

  41. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative reviewPostgrad Med. 2011;123(5):194–204. doi:10.3810/pgm.2011.09.2475

  42. Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM, Want DA. Complementary and alternative medicine use in patients before and after a cancer diagnosisCurr Oncol. 2018;25(4):e275–e281. doi:10.3747/co.25.3884

  43. Li JY, Kampp JT. Review of Common Alternative Herbal "Remedies" for Skin Cancer. Dermatol Surg.

  44. Prickett KA, Ramsey ML. Mohs micrographic surgery. In: StatPearls. StatPearls Publishing.

Additional Reading
  • Bast, R., Croce, C., Hait, W. et al. Holland-Frei Cancer Medicine. Wiley Blackwell.

  • National Cancer Institute. Melanoma Treatment (PDQ)—Health Professional Version.

  • Weller, Richard P. J. B., Hamish J.A. Hunter, and Margaret W. Mann. Clinical Dermatology. Chichester (West Sussex): John Wiley & Sons Inc.

By Timothy DiChiara, PhD
Timothy J. DiChiara, PhD, is a former research scientist and published writer specializing in oncology.